Ann: 2023 Results webinar, page-90

Whilst I understand the appeal of Big Pharma, I am not 100% convinced that TO is the best option.

This is purely because of the success rate of pharmaceuticals companies failure in this space to date.

The fact is we likely have the best people to work on this and bring it to market, in fact the likely hood of a TO event would more than likely take some of our key staff and insight to the BP.

The other thing I think is crucial is that this could be a wonder drug, which similar to Trofinitide only has to replicate phase 2 trails agin in phase 3's, Hypothetically speaking if x 3 other trails come up same as 1st PMS, results "better that could have wished for" the rate of success is low in this space, assuming we did come up with x 4 indication success would scream the quality of the 2591 drug for phase 3's almost removing any concern for failure, it then could be a case of just needing the cash by way of a partner and going through the trail process as per FDA to satisfy FDA, which would only be a time factor which if we were cashed up I don't see how it couldn't be as fast if not faster than BP.

I think if TO was their goal deal would be done by now, the longer it goes on the less chance of TO in my view.